EUVIMEDEUVIMED entdecken
Crossref

Chemistry, manufacturing, and controls strategies for antibody-targeted lipid nanoparticles

Ri Huang, Yifan Wang, Tianyu Shi, Xijun Piao, Keyun Ren, Changchang Deng, Congcong Xu

BME Horizon · 2024

DOI: 10.70401/bmeh.2026.0022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BME Horizon, 2024. Verfasst von Ri Huang und 6 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-targeted lipid nanoparticles (Ab-LNPs) represent a highly promising delivery platform for precision therapy, enabling efficient in vivo targeted delivery of nucleic acid drugs such as mRNA, DNA and siRNA. Currently, the two primary strategies for antibody functionalization of LNPs are the post-insertion method and direct surface conjugation. This review outlines the key chemistry, manufacturing, and controls challenges associated with scaling up of Ab-LNP production, with a focus on antibody modification strategies, process scale-up challenges, and quality control considerations. It aims to provide practical guidance for translating Ab-LNP technology from laboratory research to scalable manufacturing.

Zitieren

APA

Huang, R., Wang, Y., Shi, T., Piao, X., Ren, K., Deng, C., & Xu, C. (2024). Chemistry, manufacturing, and controls strategies for antibody-targeted lipid nanoparticles. BME Horizon. https://doi.org/10.70401/bmeh.2026.0022

Vancouver

Huang R, Wang Y, Shi T, Piao X, Ren K, Deng C, et al. Chemistry, manufacturing, and controls strategies for antibody-targeted lipid nanoparticles. BME Horizon. 2024. doi:10.70401/bmeh.2026.0022

BibTeX
@article{Huang2024,
  author = {Huang, Ri and Wang, Yifan and Shi, Tianyu and Piao, Xijun and Ren, Keyun and Deng, Changchang and Xu, Congcong},
  title = {Chemistry, manufacturing, and controls strategies for antibody-targeted lipid nanoparticles},
  journal = {BME Horizon},
  year = {2024},
  doi = {10.70401/bmeh.2026.0022}
}
Kostenlos starten →